The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Development trends for monoclonal antibody cancer therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Selecting and screening recombinant antibody libraries
Hoogenboom, H. R. (2005) · Nature Biotechnology · doi:10.1038/nbt1126 · Cited by 973
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., & Neuberger, M. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1351 · Cited by 607
Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Metabolic properties of IgG subclasses in man
Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 526
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Human immune response to multiple injections of murine monoclonal IgG.
Shawler, D. L., Bartholomew, R. M., Smith, L. M., & Dillman, R. O. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.1530 · Cited by 422
Antibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Monoclonal antibodies as therapeutic agents for cancer
Harris, M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01467-6 · Cited by 320
Targeted therapy of cancer with radiolabeled antibodies.
Goldenberg, D. M. (2002) · PubMed · Cited by 318
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Complement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
Kipps, T. J., Parham, P., Punt, J., & Herzenberg, L. A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.1.1 · Cited by 248
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Overview of monoclonal antibodies in cancer therapy: present and promise
Stern, M., & Herrmann, R. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.10.011 · Cited by 235
Punt, C. J., Nagy, A., Douillard, J.-Y., Figer, A., Skovsgaard, T., Monson, J., Barone, C., Fountzilas, G., Riess, H., Moylan, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09836-7 · Cited by 213
Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey, R. M., & Goldenberg, D. M. (2005) · PubMed · Cited by 200
Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M., & Kay, N. E. (1994) · Clinical Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.365-372.1994 · Cited by 184
Janas, E., Priest, R., Wilde, J. I., White, J. H., & Malhotra, R. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02720.x · Cited by 161
The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Lin, M. Z., Teitell, M. A., & Schiller, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.129.11.1 · Cited by 137
Identification and validation of cell surface antigens for antibody targeting in oncology
Carter, P. M., Smith, L. M., & Ryan, M. C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00766 · Cited by 129
Scott, A. M., Geleick, D., Rubira, M. R., Clarke, K., Nice, E. C., Smyth, F. E., Stockert, E., Richards, E. C., Carr, F. J., Harris, W. J., et al. (2000) · PubMed · Cited by 97
Baker, M. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1065 · Cited by 90
Monoclonal antibodies as therapeutics in oncology
Trikha, M., Li, Y., & Nakada, M. T. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00348-8 · Cited by 83
Progress in immunoconjugate cancer therapeutics
Payne, G. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00057-6 · Cited by 76
Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller, M. L. (2003) · PubMed · Cited by 42
Multitargeted therapy: Can promiscuity be praised in an era of political correctness?
Jimeno, A., & Hidalgo, M. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.005 · Cited by 32
Cited by
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Self-citationProperties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“They contain an N-linked oligosaccharide attached to the second heavy-chain constant domain (CH2) that is essential for antibody effector functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytolysis (CDC), and for retaining a long serum half-life.”
BackgroundInfluentialGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
“Additionally, it is estimated that ∼30% of new drugs that are likely to be licensed during the next decade will be based on antibody product”
Background
Metadata
- Authors
- Reichert, J. M., & Valge-Archer, V. E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-05
- Volume
- 6
- Issue
- 5
- Pages
- 349-356
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1988849896
- Cited by
- 389
- References
- 44
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.